Zymeworks Names Diana Hausman, M.D. Chief Medical Officer

April 26, 2016

Vancouver, Canada – Zymeworks Inc., a leader in the development of bi-specific and multi-specific antibodies, announced today that it has appointed Diana Hausman, M.D., to the newly created position of Chief Medical Officer. In this role, Dr. Hausman is responsible for overseeing clinical development and clinical strategy for the company.

“Diana joins our leadership team at a critical time as we transition to a clinical stage company, with our two leading compounds nearing first-in-human trials,” said Ali Tehrani, Ph.D., President and Chief Executive Officer of Zymeworks. “With Diana’s broad experience leading development programs in a variety of disease areas, we are well positioned to discover and bring forth new medicines for patients with cancer, autoimmune and inflammatory diseases.”

“I’m delighted to be joining the talented team at Zymeworks, which is rapidly becoming a leader in biologics drug discovery and development,” said Dr. Hausman. “This is an incredibly exciting time for the company and, given the promising preclinical data for the two Azymetric™ antibodies and propitious strategic collaborations underway, I look forward to advancing the pipeline and bringing new treatment options to patients who are otherwise ineligible for existing therapies.”

A board certified medical oncologist, Dr. Hausman brings more than 15 years of clinical drug development experience to the management team at Zymeworks. Most recently, she was Chief Medical Officer at Oncothyreon where she overaw the clinical program for their lead Phase 2 targeted anti-HER2 cancer therapy. While there, Dr. Hausman also led planning for the clinical development of a therapeutic vaccine and earlier served as the company’s vice president of clinical development. She has also held positions at Zymogenetics, Berlex, and Immunex working across multiple indications, including oncology, hematology, hepatitis C, and autoimmune disease. Dr. Hausman received her internal medicine training and specialty training in hematology and medical oncology at the University of Washington. She holds an M.D. degree from the University of Pennsylvania and an A.B. in biology from Princeton University.  

About Zymeworks Inc.

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company’s novel Azymetric™, AlbuCORE™, and EFECT™ platforms, its Zymelink™ conjugation platform and cytotoxins, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies, multivalent protein therapeutics, and antibody drug conjugates across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Contact:

Media Inquiries
Michael Lampe
(484) 575-5040
michael@scientpr.com

Investor Inquiries
Stephanie Carrington
ICR Inc.
(646)277-1282
stephanie.carrington@icrinc.com

Zymeworks Inc.
Ali Tehrani, Ph.D.
President & CEO
(604) 678-1388
info@zymeworks.com